8 results about "Mononucleosis" patented technology

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

The application discloses a prediction model for diagnosing infectious mononucleosis in children and a construction method thereof. The application adopts single factor analysis and logistic stepwise regression to screen independent influencing factors by using confirmed IM inpatient cases and suspected IM but EBV-DNA negative child cases, and adopts multiple factor regression to screen six independent influencing factors of age, ALB, GLB, PLT, LYMPH# and LYMPH% to construct a diagnosis model. Researches show that in the confirmed diagnosis scene, the multi-index combined model with blood routine and liver function has excellent diagnosis efficiency (AUC=0.986), realizes the ideal balance of high sensitivity and high specificity, provides a hierarchical tool for the precise diagnosis of IM in different clinical scenes, and is suitable for the precise diagnosis of inpatient children.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing or treating infectious mononuclear hyperplasia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: astragalus membranaceus, codonopsis pilosula, rhizoma dryopteris crassirhizomae, trollflower, semen plantaginis, mint, dandelion and liquorice. The traditional Chinese medicine composition has the effects of tonifying qi and lifting yang, nourishing blood and promoting salivation, and clearing away heat and toxic materials. Experimental results show that the traditional Chinese medicine composition can remove Epstein-Barr virus, further thoroughly eliminates the symptoms of weakness, fever, myalgia, lymphadenectasis and hepatometasis of patients, and finally realizes the curative treatment of infectious mononuclear hyperplasia, so that the traditional Chinese medicine composition has better development and utilization prospects.

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

The present invention provides multiple fluorescent probe primers and kits for simultaneously detecting multiple pathogens of central nervous system infection. Amplification primers and different fluorescent labeled Taqman fluorescent probes are designed for 9 pathogenic bacteria, including Listeria monocytogenes, Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus agalactiae, Neisseria meningitidis, coagulase-negative Staphylococcus, Staphylococcus aureus, Acinetobacter baumannii and Klebsiella pneumoniae. At the same time, human-derived internal references are added as internal quality control of the kit, so that the reagent can distinguish 3 kinds of target targets and endogenous internal reference genes in a single tube. In addition, probes and primers for coagulase-negative Staphylococci in cerebrospinal fluid can effectively detect Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus capitis, Staphylococcus saprophyticus, and Staphylococcus hemolyticus, and can be effectively distinguished from coagulase-positive Staphylococci such as Staphylococcus aureus, Staphylococcus dolphinus, Staphylococcus suis, etc.

Provided are a pharmaceutical composition comprising a delivery vehicle and at least two Epstein-Barr virus (EBV) antigen-encoding messenger ribonucleic acid (mRNA) constructs. Methods of treatment, methods of making, uses of the pharmaceutical composition, and pharmaceutical compositions comprising at least two or more EBV antigens are provided. All contemplate treating and preventing (i.e. reducing the likelihood of a symptom or a severity of a symptom of) EBV infections and EBV-associated diseases, such as infectious mononucleosis, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

This invention provides a composition comprising an LSD1 inhibitor and 1,25(OH)2D3 and its application in the treatment of acute monocytic leukemia. The composition provided by this invention can induce AML-M5 cell differentiation, achieving the therapeutic effect on acute monocytic leukemia while avoiding the side effect of hypercalcemia caused by high doses of 1,25(OH)2D3.